- Home
- ACIU vs TEAF Comparison
ACIU vs TEAF Comparison
Compare ACIU & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TEAF
- Stock Information
- Founded
- ACIU 2003
- TEAF 2017
- Country
- ACIU Switzerland
- TEAF United States
- Employees
- ACIU N/A
- TEAF N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- TEAF Finance
- Exchange
- ACIU Nasdaq
- TEAF Nasdaq
- Market Cap
- ACIU 168.7M
- TEAF 160.4M
- IPO Year
- ACIU 2016
- TEAF N/A
- Fundamental
- Price
- ACIU $2.07
- TEAF $11.83
- Analyst Decision
- ACIU Strong Buy
- TEAF
- Analyst Count
- ACIU 1
- TEAF 0
- Target Price
- ACIU $12.00
- TEAF N/A
- AVG Volume (30 Days)
- ACIU 119.1K
- TEAF 56.1K
- Earning Date
- ACIU 08-05-2025
- TEAF 01-01-0001
- Dividend Yield
- ACIU N/A
- TEAF 9.20%
- EPS Growth
- ACIU N/A
- TEAF N/A
- EPS
- ACIU N/A
- TEAF N/A
- Revenue
- ACIU $32,014,254.00
- TEAF N/A
- Revenue This Year
- ACIU N/A
- TEAF N/A
- Revenue Next Year
- ACIU $533.21
- TEAF N/A
- P/E Ratio
- ACIU N/A
- TEAF N/A
- Revenue Growth
- ACIU 91.20
- TEAF N/A
- 52 Week Low
- ACIU $1.43
- TEAF $11.11
- 52 Week High
- ACIU $4.37
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- ACIU 59.88
- TEAF 56.34
- Support Level
- ACIU $1.79
- TEAF $11.82
- Resistance Level
- ACIU $2.10
- TEAF $12.04
- Average True Range (ATR)
- ACIU 0.17
- TEAF 0.12
- MACD
- ACIU 0.00
- TEAF -0.00
- Stochastic Oscillator
- ACIU 71.93
- TEAF 54.35
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.